

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): **October 11, 2022**

**Assure Holdings Corp.**

(Exact name of registrant as specified in its charter)

<b>Nevada</b>	<b>001-40785</b>	<b>82-2726719</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
<b>7887 East Belleview Avenue, Suite 500 Greenwood Village, CO</b>		<b>80111</b>
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: **720-287-3093**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	IONM	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On October 11, 2022, Assure Holdings Corp. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value \$0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of \$1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”).

The Notice has no immediate effect on the continued listing status of the Company’s Common Stock on The Nasdaq Capital Market, and, therefore, the Company’s listing remains fully effective.

The Company is provided a compliance period of 180 calendar days from the date of the Notice, or until April 10, 2023, to regain compliance with the minimum closing bid requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). If at any time before April 10, 2023, the closing bid price of the Company’s Common Stock closes at or above \$1.00 per share for a minimum of 10 consecutive business days, subject to Nasdaq’s discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(G) to 20 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. If the Company does not regain compliance during the compliance period ending April 10, 2023, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, provided the Company meets the continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement, and notifies Nasdaq of its intent to cure the deficiency.

The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance periods. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the minimum bid price requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance or maintain compliance with the other Nasdaq listing requirements.

**Item 7.01. Regulation FD.**

On October 14, 2022, the Company issued a press release regarding performance of its first neuromonitoring case in New Jersey and its relationship with Marc J. Levine, M.D.

In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this report shall not be deemed an admission as to the materiality of any information in this report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 9.01 Exhibits****Exhibit No.      Name**

- |      |  |
|------|--|
| 99.1 | <a href="#"><u>Press Release dated October 14, 2022*</u></a>                             |
| 104  | Cover Page Interactive Data File (formatted in Inline XBRL and included as Exhibit 101). |

\* Furnished not filed pursuant to General Instruction B.2 of Form 8-K.

---

**SIGNATURE**

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ASSURE HOLDINGS CORP.**

Date: October 14, 2022

By: /s/ John Price  
Name: John Price  
Title: Chief Financial Officer

---

7887 E. Belleview Ave.  
Suite 500  
Greenwood Village, CO 80111  
(720)287-3093

## Assure Holdings Performs First Neuromonitoring Case in New Jersey

DENVER, October 14, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the **Company** or "**Assure**") (NASDAQ: IONM), a provider of intraoperative neuromonitoring ("**IONM**") and remote neurology services, is pleased to announce that it has performed its first neuromonitoring case in the state of New Jersey.

Assure will be working with Marc J. Levine, M.D., who performs approximately 200 procedures annually. Dr. Levine is a board-certified orthopedic surgeon focused on adult disorders of the cervical, thoracic and lumbar spine. His education includes a Surgical Internship at Pennsylvania Hospital, an Orthopaedic Surgery Residency at Thomas Jefferson University Hospital and a Spine Surgery Fellowship at Emory University. Dr. Levine is a current Board Member and Past President of the Medical Society of New Jersey, Immediate Past President of the Eastern Orthopaedic Association and was a founding Governing Board member of the New Jersey Surgery Center. A Clinical Assistant Professor at Rutgers New Jersey Medical School, he also serves as the Director of Orthopedic Spine Surgery at RWJBarnabas Healthcare-Hamilton.

"Assure is continuing to generate strong organic growth and will remain proactive both in expanding within states we currently serve and extending our footprint to states that present compelling opportunities. We have long targeted the Northeast for expansion with New Jersey in particular demonstrating a very strong reimbursement profile," said John A. Farlinger, Assure's executive chairman and CEO. "Our ability to secure new business with Dr. Levine reflects the strong reputation we have built in the IONM industry."

Dr. Levine commented, "A primary reason I selected Assure as my provider for intraoperative neuromonitoring services is the robust Quality Assurance program they have implemented, which emphasizes measurement, reporting and clinical quality improvement to meet the goals prioritized by the surgeons and hospitals with whom they work. Overall, Assure's exceptional clinical care and service, including investing in ongoing training and development of their clinical staff, ensure that they have the highest standards and support best possible patient outcomes."

---



7887 E. Belleview Ave.  
Suite 500  
Greenwood Village, CO 80111  
(720)287-3093

#### **About Assure Holdings**

Assure Holdings Corp. is a best-in-class provider of outsourced intraoperative neuromonitoring and remote neurology services. The Company delivers a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive procedures that place the nervous system at risk including neurosurgery, spine, cardiovascular, orthopedic and ear, nose and throat surgeries. Assure employs highly trained technologists that provide a direct point of contact in the operating room. Physicians employed through Assure subsidiaries simultaneously monitor the functional integrity of patients' neural structures throughout the procedure communicating in real-time with the surgeon and technologist. Accredited by The Joint Commission, Assure's mission is to provide exceptional surgical care and a positive patient experience. For more information, visit the company's website at [www.assureneuromonitoring.com](http://www.assureneuromonitoring.com).

#### **Forward-Looking Statements**

This news release may contain "forward-looking statements" within the meaning of applicable securities laws, including, but not limited to comments with respect to: expectations with respect to the Company's growth and development and the quality and results of future services. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company's operations and business, its remote neurology business, and economic activity in general; and risks and uncertainties discussed in our most recent annual and quarterly reports filed with the United States Securities and Exchange Commission, including our annual report on Form 10-K filed on March 14, 2022, and available on the Company's EDGAR profile at [www.sec.gov](http://www.sec.gov), which risks and uncertainties are incorporated herein by reference. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

#### **Contact**

Scott Kozak, Investor and Media Relations  
Assure Holdings Corp.  
(720) 617-2526  
[Scott.Kozak@assureiom.com](mailto:Scott.Kozak@assureiom.com)

---